Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 17
---
, 2025, and our Reports on Form 6-K, as filed with the SEC,
as described in the section titled “Incorporation of Certain Information by Reference.”

| 7 |

The Offering The following summary contains basic terms about this offering and the securities and is not intended to be complete. It may not contain all of the information that is important to you. You should read the more detailed information contained in this prospectus, including but not limited to, the risk factors beginning on page . For a more complete description of the terms of the securities, see the section of this prospectus entitled “Description of the Securities.”

| Securities offered by us |     | Units, each Unit consisting                                                                                                                    
 of one Depositary Share and one Series L Warrant to purchase one Depositary Share for cash or otherwise acquire such greater number of         
 Depositary Shares as determined in accordance with the provisions of the Series L Warrant upon a “zero exercise price” option.                 
 Under the “zero exercise price” option of the Series L Warrants, during the period of 90 calendar days following the issue                     
 date of the Series L Warrants, a holder of the Series L Warrant has the right to receive, without payment of any additional cash to the        
 Company, an aggregate number of Depositary Shares equal to the product of (x) the aggregate number of Depositary Shares that would be          
 issuable upon a cash exercise of the Series L Warrant and (y) one (1).                                                                         
 Each Series L Warrant is exercisable at an initial                                                                                             
 exercise price of $ per share (       % of the public offering price per Unit). In addition, at 4:01 p.m. Eastern time on the 7th trading day  
 after the date of issuance, or the First Reset Date, the exercise price of the Series L Warrants will be reset to a price equal to the         
 lower of (i) the exercise price then in effect and (ii) the greater of (a) 80% of lowest daily volume weighted average price, or VWAP,         
 during the period beginning on the 5th trading day after the date of issuance and ending on the First Reset Date, and (b) 40% of most          
 recent NASDAQ Official Close Price preceding execution of the Underwriting Agreement; and the number of shares issuable upon exercise          
 will be increased such that the aggregate exercise price of the Series L Warrants on the issuance date for the Depositary Shares underlying    
 the Series L